On Invalid Date, Calliditas Therapeutics Ab (NASDAQ: CALT) reported Q2 2023 earnings per share (EPS) of -$0.32, up 55.63% year over year. Total Calliditas Therapeutics Ab earnings for the quarter were -$8.47 million. In the same quarter last year, Calliditas Therapeutics Ab's earnings per share (EPS) was -$0.71.
As of Q1 2024, Calliditas Therapeutics Ab's earnings has grown year over year. Calliditas Therapeutics Ab's earnings in the past year totalled -$26.74 million.
What is CALT's earnings date?
Calliditas Therapeutics Ab's earnings date is Invalid Date. Add CALT to your watchlist to be reminded of CALT's next earnings announcement.
What was CALT's revenue last quarter?
On Invalid Date, Calliditas Therapeutics Ab (NASDAQ: CALT) reported Q2 2023 revenue of $24.81 million up 295.04% year over year. In the same quarter last year, Calliditas Therapeutics Ab's revenue was $6.28 million.
What was CALT's revenue growth in the past year?
As of Q1 2024, Calliditas Therapeutics Ab's revenue has grown 214.74% year over year. This is 45.44 percentage points higher than the US Biotechnology industry revenue growth rate of 169.3%. Calliditas Therapeutics Ab's revenue in the past year totalled $105.20 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.